Company / Capital Expenditures
Candel Therapeutics, Inc. Capital Expenditures History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$457.0K
FY2023
5-year range
$457.0K / $1.8M
FY2021-FY2023
Trend
-75.1%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $1M to $457,000 over the past 2 years.
Based on SEC 10-K filings.
$457,000 in FY2023.
Declined from $1M to $457,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, capital expenditures decreased 75.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $457.0K | -75.1% |
| FY2022 | $1.8M | +24.3% |
| FY2021 | $1.5M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026